logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

TRxADE HEALTH Subsidiary, Bonum Health, Signed a Telemedicine Service Distribution Deal with Big Y Pharmacy. See Also: Innate Pharma

TRxADE HEALTH Inc TRxADE HEALTH Inc ( MEDS ) is a health service IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey, and patient engagement in the U.S.. The firm operates the TRxADE...

Read More

July 1, 2021

0

Why Celldex Therapeutics Stock is Soaring

Celldex Therapeutics is Soaring Celldex Therapeutics ( CLDX ) stock soared following the firm’s announcement of updated data from its ongoing, open-label Phase 1b clinical trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism, which are...

Read More

July 11, 2021

0

Exelixis Latest News. See Also: TransMedics Group May Improve on Heart Transplants

Exelixis Latest News The latest news announced by Exelixis ( EXEL ) is the FDA acceptance of its New Drug Application ( NDA ) that evaluates the safety, tolerability, pharmacokinetics and preliminary antitumor activity of the firm’s investigational product XB002...

Read More

April 7, 2021

0

Immunome Inc Stock Rallied After Announcing it Neutralized the SARS-CoV-2 Delta Variant.

Immunome Inc: Neutralizing SARS-C0V-2 Delta Variant Immunome Inc ( IMNM ) is a small biotech firm whose stock soared after announcing today that its three-antibody cocktail ( IMM-BCP-01 ) demonstrated potent neutralizing activity against the SARS-CoV-2 (the virus that cause...

Read More

July 20, 2021

0

Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam

Cassava Sciences: Positive Clinical Data with SavaDX Cassava Sciences ( SAVA ) today announced positive clinical data with SavaDx, an investigational diagnostic/biomarker to detect Alzheimer’s disease with a simple blood test. SavaDx was used to measure plasma levels of altered filamin...

Read More

July 26, 2021

0

Gilead Sciences: Another Accelerated Cancer Approval from the FDA

FDA Grants Accelerated Approval for Gilead Sciences Trodelvy® The United States Food and Drug Administration ( FDA ) has granted accelerated approval of Gilead Sciences ( GILD ) product Trodelvy® (sacituzumab govitecan-hziy). The approval is for use of the product...

Read More

April 14, 2021

0

Compugen: A Small Firm with Giant Technological Capabilities

Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting Compugen ( CGEN ) announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701 , a first-in-class...

Read More

April 16, 2020

0

Why Gilead's and Moderna's Stocks Rallied Today

Gilead Sciences Gilead ( GILD ) stock soared after market hours adding $11 to the $1.90 the stock had gained during trading hours. Investors' enthusiasm was raised when very promising results came out of a clinical trial for Gilead’s drug...

Read More

April 16, 2020

0

Cassava Sciences Inc: Today's Press Releases

Cassava Sciences Inc Press Release Related to Positive Biomarker Data  Cassava Sciences Inc ( SAVA ) announced today, in a press release , positive biomarker data from an open-label study of simufilam, the Company’s investigational drug for the treatment of...

Read More

July 29, 2021

0

Compugen: A New Important Patent from Europe and Much More

Compugen: In the NEWS Compugen ( CGEN ) was granted a new patent for the composition of COM701 or backup antibodies for the treatment of cancer by the European Patent Office ( EPO ). The EPO Patent No. 3295951 titled,...

Read More

April 22, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 93
  • 94
  • 95
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy